NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW.
Genetic Analysis AS (“GA” or the “Company”) announced on November 2, 2023, that the Board of Directors of GA had successfully placed and conditionally allocated 12,396,933 new shares in the Company at a subscription price of NOK 0.79 per share (the “Directed Issue”), through which the Company may raise approximately NOK 10 million before transaction related costs. In addition, approximately NOK 0,7 million was proposed to be available for subscription by individuals from the Board of Directors and management in a separate tranche of the Directed Issue. GA, hereby, announces that members of the Board of Directors and management have subscribed for 886,074 shares in such separate tranche of the Directed Issue corresponding to a total of approximately NOK 0,7 million.
As announced on November 2, 2023, the Directed Issue included a separate tranche of up to an additional amount of NOK 0,7 million at identical terms available for subscription by individuals from the Company’s board of directors and management (“PDMRs”) (and companies controlled by such person) which due to regulatory restrictions were restricted from subscribing shares prior to publication of the Company’s 2023 Q3 report. Following the end of the subscription period in such separate tranche today November 3, 2023 at 08:30 CET, PDMRs have subscribed for 886,074 shares in the Directed Issue corresponding to a total of approximatelyNOK 0,7 million. The subscribers are:
- CEO, Ronny Hermansen via InVitroDia AS, NOK 282,000
- Chairperson, Per Matsson, NOK 100,000
- Board member, Camilla Huse Bondesson, NOK 100,000
- CFO, Eilert Aamodt via E. B. Aamodt AS, NOK 60,000
- SVP Clinical and Medical Affairs, Christina Casén, NOK 58,000
- Head of Business and Product Development, Kari Furu, NOK 50,000
- Head of Operations, Lars Tiller, NOK 50,000
Reference is made to the Company’s announcement on November 2, 2023 for further information about the Directed Issue.
Extraordinary general meeting
The Directed Issue is subject to approval by the extraordinary general meeting in the Company planned to be held on November 20, 2023. The notice for the extraordinary general meeting will also propose an authorization to the Board of Directors to be used in connection with a subsequent offering with preferential rights for shareholders, subject to applicable laws, as of the date of the Directed Issue, November 2, 2023, who were not allocated shares in the Directed Issue, as well as an authorization to raise additional capital as further described in the press release made on November 2, 2023 regarding the directed issue. Notice of the extraordinary general meeting will be published via a separate press release.
Advisors
In connection with the Directed Issue, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor and Advokatfirmaet Wiersholm AS is the Company’s Norwegian legal advisor.
Please read the full press release in English: